The present work is a retrospective study on glioblastomas treated in the Angers 
and Nice Hospital Departments of Neurosurgery between 2006 and 2007. This study 
was conducted 2 years after the audit on incident glioblastoma in France in 
2004. New events that may modify the care or survival of glioblastoma have 
occurred since 2004, justifying the present study. The results show that the 
Karnowsky Index is more often included in the clinical files and that the rate 
of complete resection has increased, indicating that neurosurgeons are becoming 
aware of neuro-oncology. Patients with total resection still have the longest 
survival (14 months). Surprisingly, less than half the patients having surgery 
received concomitant radiochemotherapy according to the Stupp protocol. Median 
overall survival remains at 9 months with intention to treat. For patients 
treated with concomitant chemoradiotherapy with temozolomide, the median 
survival is 12 months. For patients having a total resection, the median 
survival is 14 months, whatever adjuvant treatment is used. Median survival for 
patients having total resection and chemoradiotherapy with temozolomide is 18 
months, with a 23.3% 2-year survival rate, less than the ORTC trial rate.